- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Reimbursement of orphan drugs in Belgium: what (else) matters? ; volume:9 ; number:1 ; day:12 ; month:9 ; year:2014 ; pages:1-9 ; date:12.2014
Orphanet journal of rare diseases ; 9, Heft 1 (12.9.2014), 1-9, 12.2014
- Urheber
-
Picavet, Eline
- Beteiligte Personen und Organisationen
-
Cassiman, David
Simoens, Steven
SpringerLink (Online service)
- DOI
-
10.1186/s13023-014-0139-z
- URN
-
urn:nbn:de:1111-2016050125647
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Picavet, Eline
- Cassiman, David
- Simoens, Steven
- SpringerLink (Online service)
Ähnliche Objekte (12)
A systematic review of moral reasons on orphan drug reimbursement
Pricing and reimbursement of orphan drugs: the need for more transparency
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
We empower what matters
Understanding financial inclusion: What matters and how it matters
A systematic review of moral reasons on orphan drug reimbursement
Pricing and reimbursement of orphan drugs: the need for more transparency
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
We empower what matters
Understanding financial inclusion: What matters and how it matters
A systematic review of moral reasons on orphan drug reimbursement
Pricing and reimbursement of orphan drugs: the need for more transparency
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
Minority Language Rights: What Matters? A Comparison of Belgium and Canada
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
We empower what matters